Pengkajian Terapi COVID-19 Pada Pasien Rawat Inap Komorbid Hipertensi Terhadap Derajat Keparahan Penyakit di RSJPD Harapan Kita

Kurniawan, Adin Hakim; Puspita, Nanda; Meitinawati, Tri Indriyani; Lestiani, Lestiani

doi:10.20961/jpscr.v7i2.53739

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Study Design Patient Category Findings (Ivashchenko et al, Another incidence has also been reported as respiratory failure in 2/7 (28.5%) in the Favipiravir group, which was higher than the findings (0/14 and 0/5 patients) in other study groups (Zhao et al, 2021). The other study on Remdesivir also reported a similar finding, which needs careful monitoring of adverse reactions in patients with comorbid conditions and pregnancy (Siada et al, 2022;Kurniawan et al, 2022).…”

Section: Reference and Yearmentioning

confidence: 88%

Use of Favipiravir in Covid-19 Patients: A Narrative Review

Ningrum,

Fitria,

Hanur

2024

J. Pharm. Sci. Clin. Res.

View full text Add to dashboard Cite

<p><span lang="EN-US">COVID-19 is an acute respiratory disease resulting from the infection of SARS-COV-2 viruses and causes high morbidity, which requires appropriate treatment targets. Favipiravir is an antiviral that selectively inhibits RNA-dependent RNA polymerase (RdRp) of virus. This review aimed to identify several studies that prove the effectiveness and safety of using Favipiravir for COVID-19 patients. The search method used the electronic media PubMed and ScienceDirect with the keywords "Efficacy", "Favipiravir", "Treatment", "Safety", SARS-COV-2", and "Favipiravir induced", accompanied by the addition of the affixes "AND" and "OR" and selection by the publication date starting December 2019. The literature search resulted in eight (8) published articles that met the exclusion and inclusion criteria. The results of the review showed that concurrent administration of Favipiravir and Lopinavir/Ritonavir or Chloroquine, with a dosage of Favipiravir of 3200 mg/day followed by 1200 mg/day each in 2 divided doses, was considered adequate for improving the clinical symptoms of COVID-19 patients with mild-moderate symptoms in early administration. Meanwhile, administering Favipiravir with anti-IL-6 Tocilizumab for patients with severe symptoms showed a fairly good effect. The most frequently reported ADE (adverse drug events) in the use of Favipiravir were hyperuricemia and elevated alanine aminotransferase (ALT) levels. This review concluded that the best clinical response to Favipiravir is shown in COVID-19 patients with mild-to-moderate early symptoms.</span></p>

show abstract

Section: Reference and Yearmentioning

confidence: 88%

Use of Favipiravir in Covid-19 Patients: A Narrative Review

Ningrum,

Fitria,

Hanur

2024

J. Pharm. Sci. Clin. Res.

View full text Add to dashboard Cite

show abstract

“…The majority in this study confirmed mild COVID-19 patients so that the antiviral drug that was widely used was favipiravir at 70.1%. (18).…”

Section: Table I : Characteristics Of Respondents and Othermentioning

confidence: 99%

Relationship Between Patient Characteristics and Severity With the Use of Antiviral Drugs Among Covid-19 Patients at Rumah Sakit Ichsan Medical Centre Bintaro

Aulia,

Fadhilah,

Amalia

et al. 2023

MJMHS

View full text Add to dashboard Cite

Introduction: Coronavirus Disease 2019 (COVID-19) is a pandemic infectious disease caused by SARS-CoV-2 that was declared in March 2020. The goal of this study was to see if there was a link between patient characteristics (age, gender) and patient severity with the use of Covid-19 antiviral drugs in Covid-19 patients hospitalized at Rumah Sakit Ichsan Medical Center Bintaro between July and December 2021. Methods: Through retrospective data tracing, this study employed an analytical observational method with a cross sectional design. The research data was gathered from Covid-19’s medical records. With purposive sampling, the number of respondents as a sample reached 107 patients. Results: The results showed that the age range of most Covid-19 patients was 26–45 years old by 46.7%, males were more exposed to Covid-19 by 52.3%, the highest degree of severity was included in the mild category, namely 62.6%, and the highest use of antiviral was favipiravir at 70.1%. The analysis revealed that there was no significant relationship between age (p value = 0.346) and gender (p value = 0.387) with the use of Covid-19 antiviral drugs, but there was a significant relationship between patient everity and antiviral drug use (p value = 0.005). Conclusion: Finally, there is no significant relationship between age and gender with the use of Covid-19 antiviral drugs, while between the severity of patients there is a significant relationship with the use of Covid-19 antiviral drugs.

show abstract

Pengkajian Terapi COVID-19 Pada Pasien Rawat Inap Komorbid Hipertensi Terhadap Derajat Keparahan Penyakit di RSJPD Harapan Kita

Cited by 2 publications

References 18 publications

Use of Favipiravir in Covid-19 Patients: A Narrative Review

Use of Favipiravir in Covid-19 Patients: A Narrative Review

Relationship Between Patient Characteristics and Severity With the Use of Antiviral Drugs Among Covid-19 Patients at Rumah Sakit Ichsan Medical Centre Bintaro

Contact Info

Product

Resources

About